Patients with atopic dermatitis had an increased risk of COVID-19 infection despite age and sex, and some comorbidities were linked to a greater risk.

The table below is a review of notable updates that occurred in April 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Increasing physical activity is associated with a lower amyloid burden, suggesting benefits for neurological aging.

New data suggest that, in recent years, US cancer incidence has generally remained stable, and the rate of cancer deaths has generally decreased.

The observed prevalence of depressive symptoms increased after vs before 2020 among US adults, especially those aged less than 44 years.

The incidence and prevalence of atopic dermatitis among older adults increased from 1990 to 2021, although age-standardized rates decreased.

Recent data shows that most infants are receiving RSV vaccination in the US, but rates vary by race and birth month.

The use of autonomous TBP and dermoscopic device is comparable in quality to that of standard manual imaging, though it may have greater time efficiency.

Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Treatment with JAK inhibitors was associated with a greater risk of infections compared with biologic therapies in patients with atopic dermatitis.

The HHS will require all new vaccines to undergo placebo-controlled trials, likely slowing down approvals and decreasing access.

More pediatric deaths have happened in 2025 than any other year since 2009, reflecting a drop in childhood vaccination rates.